Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid

Cockbain, Andrew J.; Volpato, Milène; Race, Amanda D.; Munarini, Alessandra; Fazio, Chiara; Belluzzi, Andrea; Loadman, Paul M.; Toogood, Giles J.; Hull, Mark A.

doi:10.1136/gutjnl-2013-306445

Cited by 88 publications

(139 citation statements)

References 27 publications

Supporting

Mentioning

132

Contrasting

Order By: Relevance

“…We demonstrated that EPA-FFA 2 g daily before liver surgery was safe and well-tolerated. Analysis of resected CRCLM tissue confirmed that orally administered EPA was incorporated into target tumour tissue and was associated with a reduction in tumour vascularity as measured by CD31-positive microvessel density [8]. An intriguing preliminary observation was that EPA may provide prolonged overall survival (OS) and disease-free survival (DFS) benefit after treatment cessation following liver surgery [8].…”

Section: Introductionmentioning

confidence: 99%

“…Participants were stratified by prior fish oil supplement use and/or high dietary (> 2 oily fish portions per week) omega-3 PUFA intake. We have previously reported that dietary omega-3 PUFA intake did not change significantly in either treatment group during the trial as measured by a modified validated food frequency questionnaire [8].…”

Section: The Emt Studymentioning

confidence: 99%

“…The following FAs were measured with the relative level of each PUFA expressed as the % of the total FA content: alpha-linolenic acid (C18:33), EPA (C20:53), docosapentaenoic acid (DPA; C22:53), docosahexaenoic acid (DHA; C22:63), linoleic acid (C18:26), arachidonic acid (AA;C20:46), palmitic acid (C16:0), stearic acid (C18:0), oleic acid (C18:19). Tumour tissue PUFA content was measured previously and has been reported in the EMT study publication [8]. …”

Section: The Emt Studymentioning

confidence: 99%

“…This Phase II randomised, double-blind, placebo-controlled trial (ClinicalTrials.gov NCT01070355) has been described in detail previously [8]. Participants were randomised to EPA-FFA 2 g taken as two gastro-resistant capsules twice daily with food for a median (range) duration of 30 (12-65) days (n=43) or placebo (capric and caprylic acid triglycerides) capsules for a median 26 (15-73) days (n=45).…”

Section: The Emt Studymentioning

confidence: 99%

“…We have previously reported the results of a Phase II randomised, double-blind, placebo-controlled trial of 99% pure eicosapentaenoic acid (EPA) in the free fatty acid (FFA) form in patients undergoing liver resection surgery for colorectal cancer liver metastasis (CRCLM), called the EMT study [8]. In this 'window of opportunity' trial, gastro-resistant EPA-FFA or identical placebo capsules were taken for a variable amount of time between the decision to undergo surgery and liver resection, at which time the trial intervention was stopped.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases

Watson

Cockbain

Spencer

et al. 2016

Prostaglandins, Leukotrienes and Essential Fatty Acids

Self Cite

View full text Add to dashboard Cite

Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases, Prostaglandins Leukotrienes and Essential Fatty Acids, http://dx.doi.org/10.1016/j.plefa.2016.10.003 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. AbstractWe investigated red blood cell (RBC) PUFA profiles, and the predictive value of RBC EPA content for tumour EPA exposure and clinical outcomes, in the EMT study, a randomised trial of EPA in patients awaiting colorectal cancer (CRC) liver metastasis surgery (A.J. Cockbain et al, 2014). There was a significant increase in RBC EPA in the EPA group (n=43; median intervention 30 days; mean absolute 1.26 [±0.14]% increase; P<0.001), but not in the placebo arm (n=45). EPA incorporation varied widely in EPA users and was not explained by treatment duration or compliance.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: The Emt Studymentioning

confidence: 99%

Section: The Emt Studymentioning

confidence: 99%

Section: The Emt Studymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases

Watson

Cockbain

Spencer

et al. 2016

Prostaglandins, Leukotrienes and Essential Fatty Acids

Self Cite

View full text Add to dashboard Cite

show abstract

Fiber Intake and Survival After Colorectal Cancer Diagnosis

et al. 2018

View full text Add to dashboard Cite

show abstract

Effect of Supplementation With Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population

et al. 2020

View full text Add to dashboard Cite

Marine ω-3 fatty acid has been suggested to protect against colorectal cancer.OBJECTIVE To assess the effect of daily marine ω-3 fatty acid supplementation on the risk of colorectal cancer precursors, including conventional adenomas and serrated polyps. DESIGN, SETTING, AND PARTICIPANTSThis study was a prespecified ancillary study of the placebo-controlled randomized clinical trial VITAL . An intention-to-treat analysis was used to examine the effect of daily marine ω-3 supplements among 25 871 adults in the US general population (including 5106 African American persons) free of cancer and cardiovascular disease at enrollment. Randomization was from November 2011 to March 2014, and intervention ended as planned on December 31, 2017.INTERVENTIONS Marine ω-3 fatty acid, 1 g daily (which included eicosapentaenoic acid, 460 mg, and docosahexaenoic acid, 380 mg) and vitamin D3 (2000 IU daily) supplements. MAIN OUTCOMES AND MEASURESRisk of conventional adenomas (including tubular adenoma, tubulovillous adenoma, villous adenoma, and adenoma with high-grade dysplasia) or serrated polyps (including hyperplastic polyp, traditional serrated adenoma, and sessile serrated polyp). In a subset of participants who reported receiving a diagnosis of polyp on follow-up questionnaires, endoscopic and pathologic records were obtained to confirm the diagnosis. Odds ratios (ORs) and 95% CIs were calculated using logistic regression, after adjusting for age, sex, vitamin D treatment assignment, and use of endoscopy. Secondary analyses were performed according to polyp features and participants' characteristics. RESULTSThe demographic characteristics of participants at randomization were well balanced between the treatment and placebo groups; for example, 50.6% vs 50.5% were women, and 19.7% vs 19.8% were African American persons were included in each group. The mean (SD) age was 67.1 (7.1) years in the placebo group and 67.2 (7.1) in the ω-3 treatment group. During a median follow-up of 5.3 years (range, 3.8-6.1 years), 294 cases of conventional adenomas were documented in the ω-3 group and 301 in the control group (multivariable OR, 0.98; 95% CI, 0.83-1.15) (1:1 ratio between number of cases and number of participants). In addition, 174 cases of serrated polyps were documented in the ω-3 group and 167 in the control group (OR, 1.05; 95% CI, 0.84-1.29). Null associations were found for polyp subgroups according to size, location, multiplicity, or histology. In secondary analyses, marine ω-3 treatment appeared to be associated with lower risk of conventional adenomas among individuals with low plasma levels of ω-3 index at baseline (OR, 0.76; 95% CI, 0.57-1.02; P = .03 for interaction by ω-3 index). A beneficial association of supplementation was also noted in the African American population (OR, 0.59; 95% CI, 0.35-1.00) but not in other racial/ethnic groups (P = .11 for interaction). CONCLUSIONS AND RELEVANCE Supplementation with marine ω-3 fatty acids, 1 g per day, was not associated with reduced risk of colorectal cancer precursors. A...

show abstract

Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid

Abstract: ClinicalTrials.gov NCT01070355.

Cited by 88 publications

References 27 publications

Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases

Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases

Fiber Intake and Survival After Colorectal Cancer Diagnosis

Effect of Supplementation With Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population

Contact Info

Product

Resources

About